Evolution of resistance during first-line treatment with boosted fosamprenavir is associated with baseline mutations
- 2 January 2006
- journal article
- research article
- Published by Wolters Kluwer Health in AIDS
- Vol. 20 (1) , 138-140
- https://doi.org/10.1097/01.aids.0000198080.32207.3c
Abstract
No abstract availableThis publication has 8 references indexed in Scilit:
- Isolated lopinavir resistance after virological rebound of a ritonavir/lopinavir-based regimenAIDS, 2004
- SOLOAIDS, 2004
- Failure of lopinavir–ritonavir (Kaletra)-containing regimen in an antiretroviral-naive patientAIDS, 2004
- GW433908/ritonavir once daily in antiretroviral therapy-naive HIV-infected patientsAIDS, 2004
- Lopinavir–Ritonavir versus Nelfinavir for the Initial Treatment of HIV InfectionNew England Journal of Medicine, 2002
- Emergence of Resistance to Protease Inhibitor Amprenavir in Human Immunodeficiency Virus Type 1-Infected Patients: Selection of Four Alternative Viral Protease Genotypes and Influence of Viral Susceptibility to Coadministered Reverse Transcriptase Nucleoside InhibitorsAntimicrobial Agents and Chemotherapy, 2002
- Drug Susceptibility in HIV Infection After Viral Rebound in Patients Receiving Indinavir-Containing RegimensJAMA, 2000
- Extensive polymorphisms observed in HIV–1 clade B protease gene using high–density oligonucleotide arraysNature Medicine, 1996